{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:28:12Z","timestamp":1786994892141,"version":"build-2736575974"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T00:00:00Z","timestamp":1618272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DA039335"],"award-info":[{"award-number":["DA039335"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["GM104942"],"award-info":[{"award-number":["GM104942"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["GM132494"],"award-info":[{"award-number":["GM132494"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.neuropharm.2021.108554","type":"journal-article","created":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T22:50:05Z","timestamp":1618527005000},"page":"108554","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Gabapentin attenuates somatic signs of precipitated THC withdrawal in mice"],"prefix":"10.1016","volume":"190","author":[{"given":"M.L.","family":"Eckard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.G.","family":"Kinsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2021.108554_bib1","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0014-2999(01)00873-1","article-title":"Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55212-2","volume":"416","author":"Aceto","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108554_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2019.00228","article-title":"Use of gabapentin in the treatment of substance use and psychiatric Disorders\u00a0: a systematic review","volume":"10","author":"Ahmed","year":"2019","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.neuropharm.2021.108554_bib3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0301-0082(02)00080-1","article-title":"Retrograde signaling in the regulation of synaptic transmission\u00a0: focus on endocannabinoids","volume":"68","author":"Alger","year":"2002","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2021.108554_bib4","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1001\/jamapsychiatry.2013.3947","article-title":"Nabiximols as an agonist replacement therapy during cannabis withdrawal A randomized clinical trial","volume":"71","author":"Allsop","year":"2014","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.neuropharm.2021.108554_bib5","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1369-1600.2011.00406.x","article-title":"Pregabalin and topiramate regulate behavioural and brain gene transcription changes induced by spontaneous cannabinoid withdrawal in mice","author":"Aracil-Fern\u00e1ndez","year":"2013","journal-title":"Addiction Biol."},{"key":"10.1016\/j.neuropharm.2021.108554_bib6","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/0269881103017002004","article-title":"GABA-ergic drugs: exit stage left, enter stage right","volume":"17","author":"Ashton","year":"2003","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2021.108554_bib7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.neuropharm.2018.10.006","article-title":"Neuropharmacology THC and gabapentin interactions in a mouse neuropathic pain model","volume":"144","author":"Atwal","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2021.108554_bib8","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s002130050812","article-title":"Withdrawal following repeated exposure to d-amphetamine decreases responding for a sucrose solution as measured by a progressive ratio schedule of reinforcement","volume":"141","author":"Barr","year":"1999","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2021.108554_bib9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0014-2999(99)00792-X","article-title":"Effects of the cannabinoid CB 1 receptor antagonist , SR141716A , after D 9 -tetrahydrocannabinol withdrawal","volume":"387","author":"Beardsley","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108554_bib10","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1176\/appi.ajp.161.11.1967","article-title":"Review of the validity and significance of cannabis withdrawal syndrome","volume":"161","author":"Budney","year":"2004","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.neuropharm.2021.108554_bib11","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1037\/0021-843X.112.3.393","article-title":"The time course and significance of cannabis withdrawal","volume":"112","author":"Budney","year":"2003","journal-title":"J. Abnorm. Psychol."},{"key":"10.1016\/j.neuropharm.2021.108554_bib12","first-page":"22","article-title":"Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms","volume":"86","author":"Budney","year":"2007","journal-title":"Drugs Aging"},{"key":"10.1016\/j.neuropharm.2021.108554_bib13","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.neuron.2008.09.005","article-title":"calcium channel regulation and presynaptic plasticity","volume":"59","author":"Catterall","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2021.108554_bib14","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.1111\/bph.14055","article-title":"The monoacylglycerol lipase inhibitor KML29 with gabapentin synergistically produces analgesia in mice","volume":"174","author":"Crowe","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108554_bib15","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.beproc.2018.02.022","article-title":"Differential reinforcement of low rates differentially decreased timing","volume":"151","author":"Eckard","year":"2018","journal-title":"Behav. Process."},{"key":"10.1016\/j.neuropharm.2021.108554_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172966","article-title":"Precipitated \u03949-THC withdrawal reduces motivation for sucrose reinforcement in mice","volume":"195","author":"Eckard","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2021.108554_bib17","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/BF02244046","article-title":"Animal models of drug withdrawal symptoms","volume":"101","author":"Emmett-Oglesby","year":"1990","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2021.108554_bib18","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/sj.bjp.0703380","article-title":"Inhibition of neuronal Ca 2 + influx by gabapentin and subsequent reduction of neurotransmitter release from rat neocortical slices","volume":"130","author":"Fink","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108554_bib19","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.biopsych.2014.09.008","article-title":"The central amygdala as an integrative hub for anxiety and alcohol use disorders","volume":"77","author":"Gilpin","year":"2015","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2021.108554_bib20","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/WNR.0000000000000382","article-title":"Gabapentin alleviates affective pain after traumatic nerve injury","volume":"26","author":"Griggs","year":"2015","journal-title":"Neuroreport"},{"key":"10.1016\/j.neuropharm.2021.108554_bib21","first-page":"736","article-title":"Predictors of marijuana relpase in the human laboratory: robust impact of tobacco cigarette smoking status","volume":"32","author":"Haney","year":"2013","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2021.108554_bib22","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/npp.2013.54","article-title":"Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse","volume":"38","author":"Haney","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2021.108554_bib23","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s00213-007-1020-8","article-title":"Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse","volume":"197","author":"Haney","year":"2008","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2021.108554_bib24","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1038\/npp.2009.114","article-title":"Suppression of amygdalar endocannabinoid signaling by stress contributes to activation of the hypothalamic-pituitary-adrenal axis","volume":"34","author":"Hill","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2021.108554_bib25","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.pbb.2006.02.023","article-title":"Effects of terguride, ropinirole, and acetyl-l-carnitine on methamphetamine withdrawal in the rat","volume":"83","author":"Hoefer","year":"2006","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2021.108554_bib26","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.2174\/092986710790980023","article-title":"CB 1 cannabinoid receptors and their associated proteins","volume":"17","author":"Howlett","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.neuropharm.2021.108554_bib27","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/sj.bjp.0702228","article-title":"Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with \u0394-9-tetrahydrocannabinol","volume":"125","author":"Hutcheson","year":"1998","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108554_bib28","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1007\/s00213-014-3611-5","article-title":"Lithium carbonate in the management of cannabis withdrawal\u00a0: a randomized placebo-controlled trial in an inpatient setting","volume":"231","author":"Johnston","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2021.108554_bib29","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.intimp.2014.09.029","article-title":"Gabapentin-induced changes of plasma cortisol level and immune status in hysterectomized women","volume":"23","author":"Karbi\u0107","year":"2014","journal-title":"Int. Immunopharm."},{"key":"10.1016\/j.neuropharm.2021.108554_bib30","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0028-3908(86)90240-6","article-title":"Prolonged CNS hyperexcitability in mice after a single exposure to delta-9-tetrahydrocannabinol","volume":"25","author":"Karler","year":"1986","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2021.108554_bib31","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1476-5381.1980.tb14562.x","article-title":"Subacute cannabinoid treatment: anticonvulsant activity and withdrawal excitability in mice","volume":"68","author":"Karler","year":"1980","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108554_bib32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pbb.2010.12.002","article-title":"Inhibition of endocannabinoid catabolic enzymes elicits anxiolytic-like effects in the marble burying assay","volume":"98","author":"Kinsey","year":"2011","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2021.108554_bib33","article-title":"Corticotropin-releasing hormone stimulates Ca2+ entry through L- and P-type Ca2+ channels in rat corticotropes","volume":"13","author":"Kuryshev","year":"1996","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuropharm.2021.108554_bib34","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.drugalcdep.2010.12.010","article-title":"Dronabinol for the treatment of cannabis dependence\u00a0: a randomized","volume":"116","author":"Levin","year":"2011","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2021.108554_bib35","first-page":"53","article-title":"Dronabinol and lofexidine for cannabis use disorder","volume":"159","author":"Levin","year":"2016","journal-title":"A randomized"},{"key":"10.1016\/j.neuropharm.2021.108554_bib36","first-page":"181","volume":"vol. 69","author":"Lichtman","year":"2001"},{"key":"10.1016\/j.neuropharm.2021.108554_bib37","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/FBP.0000000000000187","article-title":"Separate and combined effects of gabapentin and 9THC in humans discriminating 9THC","volume":"27","author":"Lile","year":"2016","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108554_bib38","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.drugalcdep.2018.09.005","article-title":"DSM-5 cannabis withdrawal syndrome: demographic and clinical correlates in U.S. adults","volume":"195","author":"Livne","year":"2019","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2021.108554_bib39","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/sj.bjp.0704227","article-title":"Block by gabapentin of the facilitation of glutamate release from rat trigeminal nucleus following activation of protein kinase C or adenylyl cyclase","volume":"134","author":"Maneuf","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108554_bib40","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/13543784.2018.1417383","article-title":"Gabapentin for the treatment of alcohol use disorder","volume":"27","author":"Mason","year":"2018","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.neuropharm.2021.108554_bib41","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1038\/npp.2012.14","article-title":"A proof-of-concept randomized controlled study of Gabapentin\u00a0: effects on cannabis use , withdrawal and executive function deficits in cannabis-dependent adults","volume":"37","author":"Mason","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2021.108554_bib42","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/jamainternmed.2013.11950","article-title":"Gabapentin treatment for alcohol dependence A randomized clinical trial","volume":"174","author":"Mason","year":"2014","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.neuropharm.2021.108554_bib43","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/adb.12350","article-title":"Topiramate and motivational enhancement therapy for cannabis use among youth: a randomized placebo-controlled pilot study","volume":"22","author":"Miranda","year":"2017","journal-title":"Addiction Biol."},{"key":"10.1016\/j.neuropharm.2021.108554_bib44","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.neuropharm.2016.08.020","article-title":"Emotional arousal state influences the ability of amygdalar endocannabinoid signaling to modulate anxiety","volume":"111","author":"Morena","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2021.108554_bib45","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008940.pub3","article-title":"Pharmacotherapies for cannabis dependence (Review )","author":"Nielsen","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2021.108554_bib46","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1528-1157.1997.tb01728.x","article-title":"GABA and epileptogenesis","volume":"38","author":"Olsen","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2021.108554_bib47","doi-asserted-by":"crossref","first-page":"5431","DOI":"10.1210\/en.2004-0638","article-title":"Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis","volume":"145","author":"Patel","year":"2004","journal-title":"Endocrinology"},{"key":"10.1016\/j.neuropharm.2021.108554_bib48","series-title":"Textbook of Addiction Treatment: International Perspectives","first-page":"367","article-title":"Treatment of cannabis use disorders","author":"Ramesh","year":"2015"},{"key":"10.1016\/j.neuropharm.2021.108554_bib49","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.biopsych.2009.11.007","article-title":"Corticotropin releasing factor \u2013 induced amygdala gamma-aminobutyric acid release plays a key role in alcohol dependence","volume":"67","author":"Roberto","year":"2010","journal-title":"Biol. Psychiatr."},{"key":"10.1016\/j.neuropharm.2021.108554_bib50","doi-asserted-by":"crossref","first-page":"5762","DOI":"10.1523\/JNEUROSCI.0575-08.2008","article-title":"Cellular and behavioral interactions of gabapentin with alcohol dependence","volume":"28","author":"Roberto","year":"2008","journal-title":"J. Neurosci."},{"issue":"276","key":"10.1016\/j.neuropharm.2021.108554_bib51","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1126\/science.276.5321.2050","article-title":"Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal","volume":"80","author":"Rodr\u00edguez De Fonseca","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2021.108554_bib52","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s40263-014-0164-4","article-title":"Misuse and abuse of pregabalin and gabapentin: cause for concern?","volume":"28","author":"Schifano","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2021.108554_bib53","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1208\/s12248-009-9110-7","article-title":"Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice","volume":"11","author":"Schlosburg","year":"2009","journal-title":"AAPS J."},{"key":"10.1016\/j.neuropharm.2021.108554_bib54","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.coph.2005.11.003","article-title":"The mechanisms of action of gabapentin and pregabalin","volume":"6","author":"Sills","year":"2006","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108554_bib55","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.chc.2016.03.003","article-title":"Cannabis use disorder in adolescence","volume":"25","author":"Simpson","year":"2016","journal-title":"Child Adolesc. Psychiatry Clin. NA"},{"key":"10.1016\/j.neuropharm.2021.108554_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02805968","article-title":"The antiepileptic agent gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by D-serine","volume":"127","author":"Singh","year":"1996","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2021.108554_bib57","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/BF00428203","article-title":"The tail suspension test: a new method for screening antidepressant in mice","volume":"85","author":"Steru","year":"1985","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2021.108554_bib58","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/sj.bjp.0704439","article-title":"Gabapentin inhibits high-threshold calcium channel currents in cultured rat dorsal root ganglion neurones","volume":"135","author":"Sutton","year":"2002","journal-title":"Br. J. Pharmcology"},{"key":"10.1016\/j.neuropharm.2021.108554_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2006.09.008","article-title":"Pharmacology and mechanism of action of pregabalin\u00a0: the calcium channel alpha 2 \u2014 delta1 subunit as a target for antiepileptic drug discovery","volume":"73","author":"Taylor","year":"2007","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2021.108554_bib60","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.pbb.2018.12.009","article-title":"CB1 positive allosteric modulation attenuates \u03949-THC withdrawal and NSAID-induced gastric inflammation","volume":"177","author":"Trexler","year":"2019","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2021.108554_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2018.05.029","article-title":"Novel behavioral assays of spontaneous and precipitated THC withdrawal in mice","author":"Trexler","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.neuropharm.2021.108554_bib62","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1152\/jn.1997.78.1.43","article-title":"Cannabinoids inhibit N- and P\/Q-Type calcium channels in cultured rat hippocampal neurons","volume":"78","author":"Twitchell","year":"1997","journal-title":"J. Neurophysiol."},{"key":"10.1016\/j.neuropharm.2021.108554_bib63","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.neuropharm.2017.07.017","article-title":"P\/Q-type voltage-gated calcium channels mediate the ethanol and CRF sensitivity of central amygdala GABAergic synapses","volume":"125","author":"Varodayan","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2021.108554_bib64","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s40263-018-0577-6","article-title":"A systematic review of the efficacy of cannabinoid agonist replacement therapy for cannabis withdrawal symptoms","volume":"32","author":"Werneck","year":"2018","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2021.108554_bib65","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1210\/endo-87-2-426","article-title":"Role of calcium ions in the release of ACTH from rat pituitary tissue in vitro","volume":"87","author":"Zimmerman","year":"1970","journal-title":"Endocrinology"}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821001088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821001088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:12:30Z","timestamp":1758438750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390821001088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":65,"alternative-id":["S0028390821001088"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108554","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gabapentin attenuates somatic signs of precipitated THC withdrawal in mice","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108554","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108554"}}